Previous studies have reported that blocking CBR-1 signaling inhibits cancer growth in mantle cell lymphoma, thyroid, colon, and breast cancers in vitro and in vivo (Portella et al. 2003; Flygare 2005; Sarnataro et al. 2006; Santoro 2009; Luo 2019; Faiz et al. 2024). Here, CBR1 is linked to breast carcinoma.